Odiparcil

Drug Profile

Odiparcil

Alternative Names: 424323; IVA336; SB 424323

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; GlaxoSmithKline; Inventiva Pharma; Solvay
  • Class Antithrombotics; Glycosides; Small molecules
  • Mechanism of Action Glycosaminoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis VI
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis VI
  • Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis

Most Recent Events

  • 29 Aug 2017 Odiparcil receives Orphan Drug status for Mucopolysaccharidosis VI in European Union
  • 10 Aug 2017 Odiparcil receives Orphan Drug status for Mucopolysaccharidosis VI in USA
  • 10 Aug 2017 Inventiva Pharma plans a phase IIa iMProveS trial for Mucopolysaccharidosis VI at two European Union sites in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top